By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Consultant in tears as he tells inquest that likely cause of a patient's death was low blood sugar by administration of ...
ASCO 2026 cancer breakthroughs from Chicago include daraxonrasib nearly doubling survival in metastatic pancreatic cancer, ...
Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...
Erasca disclosed a potentially treatment-related death in its Phase 1 ERAS-0015 trial, and its stock plummeted 48% on the ...
Colorectal cancer rates are rising among young adults. A groundbreaking clinical trial offers hope, as one patient sees ...
A nurse prepares a patient for chemotherapy. (Fly View Productions/E+/Getty Images) The human population is growing larger ...
Results showed that tumours shrank in 20 per cent of patients. Crucially, the cancer ceased growing in almost nine out of 10 ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results